US 12,043,662 B2
Angiopoietin 2, VEGF dual antagonists
Yuefeng Lu, Newbury Park, CA (US); and Jian-Feng Lu, Oak Park, CA (US)
Assigned to AskGene Pharma Inc., Camarillo, CA (US)
Filed by AskGene Pharma Inc., Camarillo, CA (US)
Filed on Jul. 13, 2021, as Appl. No. 17/374,960.
Application 17/374,960 is a continuation of application No. 16/380,852, filed on Apr. 10, 2019, granted, now 11,059,885.
Application 16/380,852 is a continuation in part of application No. 15/593,280, filed on May 11, 2017, granted, now 10,654,922.
Claims priority of provisional application 62/655,436, filed on Apr. 10, 2018.
Claims priority of provisional application 62/336,522, filed on May 13, 2016.
Claims priority of provisional application 62/448,998, filed on Jan. 21, 2017.
Claims priority of provisional application 62/459,046, filed on Feb. 14, 2017.
Prior Publication US 2022/0041705 A1, Feb. 10, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/22 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01)
CPC C07K 16/22 (2013.01) [A61K 9/08 (2013.01); A61K 9/19 (2013.01); C07K 2317/55 (2013.01); C07K 2317/622 (2013.01)] 2 Claims
 
1. A method of treating a human patient with proliferative retinopathy, wet age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), or diabetic retinopathy (DR) comprising administering to the patient a pharmaceutical composition comprising a chimeric molecule comprising:
a) a variable light chain (VL) polypeptide comprising an amino acid sequence that is at least 95% identical to the amino acid sequence set forth in SEQ ID NO: 4, wherein the VL polypeptide comprises complementary-determining region (CDR) sequences having the amino acid sequences of SASQDISNYLN (SEQ ID NO: 65), FTSSLHS (SEQ ID NO: 66), and QQYSTVPWT (SEQ ID NO: 67); and
b) a variable heavy chain (VH) polypeptide comprising an amino acid sequence that is at least 99% identical to the amino acid sequence set forth in SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, or SEQ ID NO: 51, wherein the VH polypeptide comprises CDR sequences having the amino acid sequences of GYDFTHYG (SEQ ID NO: 68), INTYTGEP (SEQ ID NO: 69), and YCAKYPYYYGTSHWYFDV (SEQ ID NO: 70).